It is made available under a CC-BY-NC-ND 4.0 International license .

1 TITLE

- 2 Prevalence and risk factors for long COVID after mild disease: a longitudinal study with a
- 3 symptomatic control group.
- 4

5 AUTHORS

- 6 > Ana Beatriz Cazé Cerón <u>ana.caze@ufba.br</u> Universidade Federal da Bahia,
 7 Salvador, Bahia, Brazil
- 8 > Thiago Cerqueira-Silva, MD <u>csilvathiago@hotmail.com</u> LIB and LEITV
 9 Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil;
 10 Universidade Federal da Bahia, Salvador, Bahia, Brazil
- Adriele Pinheiro Bomfim, M. Sc., <u>adrielepbomfim@gmail.com</u> Instituto Gonçalo
 Muniz, Fiocruz, Salvador, Brazil; Universidade Federal da Bahia, Salvador, Bahia,
 Brazil
- 14 > Gisley Lima de Souza <u>gisleysouza19.1@bahiana.edu.br</u> Escola de Medicina e
 15 Saúde Pública da Bahia; Instituto Goncalo Moniz, Fiocruz, Salvador, Bahia, Brazil
- 16 > Amanda Canário Andrade Azevedo, MD, M.Sc. <u>amandacanario@gmail.com</u> 17 Hospital Santa Izabel, Santa Casa da Bahia, Salvador, Bahia, Brazil
- 18 Michelle Queiroz Aguiar Brasil, MD, M. Sc. <u>michelleqas@gmail.com</u> Instituto
 19 Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil; Federal University of Bahia,
 20 Salvador, Bahia, Brazil
- 21 > Nara Rúbia Santos <u>narabusiness@hotmail.com</u> Departamento de Vigilância em
 22 Saúde/Vigilância Epidemiológica, Campo Formoso, Bahia Brazil
- Antônio Ricardo Khouri Cunha, PhD <u>ricardo_khouri@hotmail.com</u> Department of
 Microbiology, Immunology and Transplantation, Rega Institute for Medical Research,
 Laboratory of Clinical and Epidemiological Virology, Belgium; Instituto Gonçalo
- 26 Moniz, Fiocruz, Salvador, Bahia, Brazil

27	\blacktriangleright	Jennifer Dan, MD, PhD – jdan@ucsd.edu - Center for Infectious Disease and Vaccine
28		Research, la Jolla Institute for Immunology (LJI); Department of Medicine, Division
29		of Infectious Disease and Global Public Health, University of California, San Diego
30		(UCSD), La Jolla, CA 92037, USA
31	۶	Antonio Carlos Bandeira, MD, PhD, - antoniobandeira@gmail.com - UNI-FTC-
32		Faculdade Tecnologia Ciências Medical School, Bahia; Central State Laboratory
33		LACEN-Bahia; Infectious Diseases Advisor
34	۶	Luciano Pamplona de Goes Cavalcanti, MD, PhD - pamplona.luciano@gmail.com -
35		Universidade Federal do Ceará, Fortaleza, Ceará, Brazil; Centro Universitario
36		Christus, Fortaleza, Ceará, Brazil
37	۶	Manoel Barral-Netto, MD, PhD - manoel.barral@fiocruz.br - LIB and LEITV
38		Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil;
39		Universidade Federal da Bahia, Salvador, Bahia, Brazil
40	≽	Aldina Maria Prado Barral - aldina.barral@fiocruz.br - Instituto Gonçalo Moniz,
41		Fundação Oswaldo Cruz, Salvador, Bahia, Brazil; Instituto de Investigação em
42		Imunologia, São Paulo, São Paulo, Brazil
43	۶	Cynara Gomes Barbosa*, PhD - cynara.barbosa@gmail.com - Universidade Federal
44		da Bahia, Salvador, Brazil
45		Viviane Sampaio Boaventura de Oliveira*, MD, PhD, - vsboaventura@gmail.com -
46		LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia,
47		Brazil; Universidade Federal da Bahia, Salvador, Bahia, Brazil
48		*Those authors equally supervised this study
49	Corre	sponding author
50	Vivian	e Sampaio Boaventura
51	Email	address: <u>vsboaventura@gmail.com</u>

- 52 Telephone: + 55 71 31762211
- 53 Postal address: 121 Waldemar Falcão Street, Candeal, Salvador, Bahia, Brazil, CEP 40296
- 54
- 55
- 56

It is made available under a CC-BY-NC-ND 4.0 International license .

57	ABSTRA	СТ

58

59 Background

60 There is limited data on the prevalence and risk factors for long COVID, with a shortage of

61 prospective studies with appropriate control groups and adequate sample size. We therefore

62 performed a prospective study to determine the prevalence and risk factors for long COVID.

63 *Methods*

We recruited patients age ≥ 15 years who were clinically suspected of having acute SARS-CoV-2 infection from September 2020 to April 2021. Nasopharyngeal swabs were collected for RT-PCR 3-5 days post symptom onset. Clinical and sociodemographic characteristics were collected using structured questionnaires from persons positive and negative for SARS-COV-2. Follow-up was performed by telephone interview to assess early outcomes and persistent symptoms. For COVID-19 cases, 5D-3L EuroQol questionnaire was used to assess the impact of symptoms on quality of life.

71 Results

72 We followed 814 participants (412 COVD-19 positive and 402 COVID-19 negative persons) 73 of whom the majority (741 / 814) had mild symptoms. Both the COVID-19 positive and the 74 COVID-19 negative groups had similar sociodemographic and clinical characteristics, except 75 for the rate of hospitalization (15.8% vs 1.5%, respectively). One month after disease onset, 76 122 (29.6%) individuals reported residual symptoms in the COVID-19 positive group or the 77 long COVID group versus 24 (6%) individuals in the COVID-19 negative group. In the long 78 COVID group, fatigue, olfactory disorder, and myalgia were the most frequent symptoms 79 which occurred in the acute phase. Compared to recovered patients, female sex, older age and 80 having > 5 symptoms during the acute phase were risk factors for long COVID. Quality of 81 life was evaluated in 102 out of 122 cases of long COVID with 57 (55.9%) reporting an 82 impact in at least one dimension of the EuroQol 5D-3L questionnaire.

It is made available under a CC-BY-NC-ND 4.0 International license .

83 *Conclusion*

84 In this prospective study consisting predominantly of patients with mild disease, the

85 persistence of symptoms after acute disease was highly associated with long COVID-19

- 86 (29.6% vs 6% of COVID negative group). The risk factors for long COVID were older age,
- 87 female sex, and polysymptomatic acute disease.
- 88

89 KEYWORDS

- 90 COVID-19; SARS-CoV-2; long COVID; frequency; risk factor; outpatients; post-COVID
- 91 syndrome; persistent symptoms; post-Acute COVID Syndrome; PASC.
- 92
- 93

It is made available under a CC-BY-NC-ND 4.0 International license .

94 BACKGROUND

95 Long COVID has received less attention from the scientific community than acute 96 COVID-19, representing less than 2% of COVID-19 publications in PubMed Clinical 97 Queries, August 31, 2022). Several important aspects remain undefined such as its 98 prevalence. Long COVID has been reported to effect between 7.5% to 89% of patients [1, 2, 99 29, 30]. Most of these studies do not include well-matched controls which is important 100 because long COVID-symptoms are nonspecific and may be attributed to other factors such 101 as the physical and mental impact of having COVID-19 infection or hospitalization [3,4]. 102 Prospective studies enrolling symptomatic individuals with and without confirmed COVID-103 19 are necessary to better estimate the prevalence of long COVID and its associated risk 104 factors.

Long COVID is anticipated to have a large impact on the healthcare system [5]. Identifying risk factors for developing long COVID will help mitigate its impact. Some risk factors have been suggested for long COVID; however, these studies consisted of previously hospitalized patients [1] or were retrospective analyses from electronic health records of not hospitalized patients (31). We therefore performed a longitudinal study of patients with COVID-like symptoms who tested positive or negative for SARS-CoV-2 to assess the prevalence and risk factors for long COVID and its impact on the quality of life.

112

113 **METHODS**

114 Study population

115 We recruited individuals age \geq 15 years with clinical suspicion of acute SARS-CoV-2 116 infection in health care units from three municipalities of Bahia State-Brazil (Irecê, Campo 117 Formoso, and Lauro de Freitas). Individuals who had difficulty in reporting symptoms, those 118 who were > 20 days post symptom onset at the time of recruitment, or those who reported

6/26

It is made available under a CC-BY-NC-ND 4.0 International license .

- 119 SARS-CoV-2 re-infection were excluded. The study was conducted from September 2020 to
- 120 April 2021. The ancestral strain or gamma variant of SARS-CoV-2 was dominant in Brazil
- 121 from November 2020 to August 2021 (Additional file 1: Fig S1-2) [6].
- 122
- 123 Exposure measurement

All patients were tested for COVID-19 by nasopharyngeal RT-PCR. Only individuals who had an RT-PCR in the first ten days of disease onset were considered eligible for the follow-up. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) protocol was followed.

128

129 Recruitment strategy and data collected

130 Consecutive in-person recruitment included the application of a structured survey 131 (Questionnaire 1) using Research Electronic Data Capture (REDCap) software hosted by the 132 Gonçalo Moniz Institute (IGM/FIOCRUZ) in Bahia, Brazil. The following information was 133 collected: sociodemographic characteristics (age, gender, skin color, body mass index, 134 anthropometric data, municipality of residence), comorbidities (hypertension, diabetes, heart 135 disease, chronic lung disease, other), date of symptom onset, acute symptoms (fever, 136 myalgias, arthralgias, cough, shortness of breath, nasal congestion, sneezing, coryza, sore 137 throat, sinus pain, retroocular pain, ear pain, headache, chest pain, chest discomfort, rash, 138 abdominal pain, loss of appetite, vomiting, diarrhea (2 or more episodes in the last 24 hours), 139 weakness, fatigue, lightheadedness or fainting, loss of smell, and loss of taste).

140

141 *Follow-up and outcome measurement*

SARS-CoV-2 positive (COVID-19) and negative (non-COVID-19) patients who
 reported COVID-like symptoms were followed. Negative cases were recruited on the same

It is made available under a CC-BY-NC-ND 4.0 International license .

day as positive cases before nasopharyngeal RT-PCR. The date of symptom onset was considered Day zero. A second structured questionnaire (Questionnaire 2) was conducted 30 to 60 days after disease onset by telephone to document the RT-PCR result, acute symptoms, and clinical outcome. Participants were classified as non-hospitalized or hospitalized in the intensive care unit (ICU) or non-ICU). To avoid memory bias, questionnaires 1 and 2 were applied in a short interval of time.

A third structured questionnaire was conducted 60 to 250 days after disease onset by telephone to evaluate residual symptoms (Questionnaire 3). Questions included residual or new symptoms: cough, fatigue, shortness of breath, headache, chest pain, dysphonia, dysphagia, loss of appetite, loss of smell, loss of taste, myalgias, arthralgias, fever, and other non-listed symptoms. Patients reporting suspected or confirmed re-infection were excluded from the final analysis. A schematic diagram of the study is provided (**Additional file 1: Fig S3**).

157

158 Outcomes of interest

Long COVID was defined according to the Centers for Disease Control and Prevention classification [7]. Persistence of symptoms was defined as the presence of at least one residual symptom > 1 month post disease onset. The list of residual symptoms presented on the questionnaire was based on literature [8,9].

163 The European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) was conducted via 164 telephone to assess health dimensions: mobility, self-care, daily activities, pain/discomfort 165 and anxiety/depression. The EQ-visual analogue scale (VAS) was also conducted with 0 166 rated as worst health imaginable and 100 as the best imaginable health [10].

167

168 Statistical analysis

It is made available under a CC-BY-NC-ND 4.0 International license .

Categorical data were described using absolute values and percentages/frequencies. Continuous data were described using mean (standard deviation, SD) and median (interquartile range, IQR). The correlation matrix was constructed based on the frequency of persistent symptoms reported by the patients. Multivariable logistic regression was performed to explore risk factors related to long COVID, applying the odds ratios (OR; 95% CI). Analyses were done in R (version 4.2.0) [26].

175

176 **RESULTS**

177 In total, 1,268 patients with suspected SARS-CoV-2 infection were recruited and 178 answered the first questionnaire 4 days (range of 3-5 days) post symptom onset. After 179 excluding cases outside the RT-PCR recommended window period, reported re-infection, or 180 those lost to follow-up, 814 (64.2%) patients were considered eligible for the analysis of 181 residual symptoms (Fig. 1, Additional file 1: Fig. S3). Questionnaires 2 and 3 were 182 conducted 40 (31-59) days and 102 (63-150) days post symptom onset, respectively. No 183 difference in sociodemographic data and frequency of positive RT-PCR were observed 184 between the included (n=814) and excluded (n=454) participants (Additional file 1: Table 185 S1). Among the included participants, 412 tested positive (COVID-19 group) and 402 tested 186 negative (non-COVID-19 group) for SARS-CoV-2. Demographic characteristics for the 187 COVID and non-COVID groups were as follows, respectively: a median age of 36 (IQR) and 188 34 (IQR) years, female gender of 55% and 64%, mild disease in 84% and 99% (Table 1). 189 More patients were hospitalized in the COVID-19 group compared to the non-COVID-19 190 group (15.9% vs 1.5%, respectively, **Table 1**). Follow-up time was 3.3 months for the 191 COVID group and 3.7 months for the non-COVID group (Additional file 1: Fig. S4).

192After one month post disease onset, per the CDC definition for long COVID193(September 16, 2021), 122/412 (29.6%) individuals from the COVID group reported residual

It is made available under a CC-BY-NC-ND 4.0 International license .

194 symptoms and were classified as long COVID cases, while the remaining 290 individuals 195 were fully recovered. From the non-COVID group, residual symptoms were reported by only 196 24 (6%) individuals (Table 1). Among long COVID cases, 57 (13.2%) presented with more 197 than two residual symptoms. 198 Within the COVID group, fatigue (56, 13.7%), olfactory disorder (42, 9.9%), myalgia 199 (36, 8.7%), gustatory disorder (27, 6.6%), and headache (26, 6.1%) were the residual 200 symptoms most frequently reported (Fig. 2). These symptoms started mainly during the acute 201 phase. Other symptoms not reported during the acute phase, such as memory loss and hair 202 loss, were reported by the patients with long COVID (Additional file 1: Table S2). 203 Compared to those who recovered, the long COVID group had more women (63.1% vs. 204 52.1%) and older individuals [40 (32-51) vs. 35 (28-47) years] (**Table 2**). Hospitalization for 205 acute disease was comparable between long COVID (21/122, 17.2%) and recovered patients 206 (44/290, 15.2%).

The risk of long COVID increased with age and was significant for persons 50 years of age or older (OR 2.44, 95% CI 1.29-4.66). Individuals with > five symptoms in the acute phase (OR 3.15, 95% CI 1.37-8.55) and females (OR 1.55, 95% CI 0.99-2.44) were more likely to develop long COVID (**Table 3**).

211 Co-occurrence of long COVID symptoms was also observed. Fatigue was reported by 212 at least 50% of those that complained of gustatory dysfunction, anorexia, dysphonia, chest 213 pain, headache, breathlessness, or myalgia. Moreover, olfactory dysfunction was reported by 214 80% of participants with gustatory dysfunction (**Additional file 1: Fig. S5**).

Finally, we have evaluated the impact of long COVID on the quality of life. The EQ-5D-3L questionnaire was administered to 102 out of 122 patients. Fifty-seven patients (55.8%) reported alteration in at least one dimension of QoL, and 41 patients (41.1%) had an impact in the dimension of pain and depression (**Additional file 1: Table S3**).

It is made available under a CC-BY-NC-ND 4.0 International license .

219

220 **DISCUSSION**

221 We have followed RT-PCR positive and negative patients with COVID-like 222 symptoms from the first days post symptom onset to 63-150 days post symptom onset to 223 determine the prevalence of long COVID-19. Long COVID occurred in almost one-third of 224 test-positive cases, the majority with mild acute disease, compared to 6% of negative patients 225 with residual symptoms, supporting the association between SARS-CoV-2 infection and 226 residual symptoms. The risk of long COVID increased with age > 50 years old, female 227 gender, and the development of > five symptoms during the acute phase. Together these 228 findings demonstrate that residual symptoms after mild disease were mainly associated with 229 COVID-19 with well-defined demographic and clinical risk factors.

230 The proportion of patients with COVID-19 who developed long COVID has varied 231 from 7.5% to 89% [1, 2, 29, 30]. Most studies only included patients who tested positive for 232 SARS-CoV-2. One strength of our study is the inclusion of a comparator group of 233 symptomatic patients, recruited in the same time/location, who tested negative by SARS-234 CoV-2 RT-PCR. Additionally, most symptoms investigated in the follow-up questionnaires 235 were evaluated at the time of recruitment, in a blinded manner, prior to the SARS-CoV-2 test 236 result. The inclusion of a control group is important considering that many residual 237 symptoms attributed to long COVID, such as fatigue and headache, are nonspecific and could 238 be triggered or aggravated by stress and psychosocial problems connected to the global health 239 crisis [11-13]. Indeed, we observed that non-confirmed COVID-19 cases reported similar 240 residual symptoms after acute illness, albeit at a much lower frequency. Few studies have 241 included a control group composed of symptomatic patients that tested negative for SARS-242 CoV-2 [14, 31]. In a cohort of healthcare workers, olfactory disorders and hair loss were 243 related to long COVID while positive and negative cases both had similar frequencies of

It is made available under a CC-BY-NC-ND 4.0 International license .

exhaustion/burnout and fatigue [14]. In a population-based digital retrospective cohort including outpatients and well-matched controls, 62 symptoms were associated with long COVID [31]. The inclusion of a control group is even more valuable for hospitalized cases, considering the increased risk of sequelae associated with iatrogenic procedures for treating severe disease [15]. Together, these findings highlight the importance of including a control group when determining the frequency of sequelae to avoid overestimating long COVID cases.

We observed a similar proportion of long COVID in groups with mild and moderate/severe disease [16,17]. We enrolled a small number of severe COVID-19 cases and therefore could not conclude an association between disease severity and sequelae. Severe COVID-19 increases the risk of long COVID by 1.2 to 8x among hospitalized cases compared to those not hospitalized [18]. Nonetheless, the finding that long COVID occurs in a significant proportion of individuals after mild disease highlights its potential impact on the healthcare system, as COVID-19 variants and sub-variants continue to spread worldwide.

Fatigue was the most frequent sequelae and occurred isolated or associated with other clinical manifestations. As previously reported [19], we also observed a vast impact of long COVID on the quality of life. Although the mechanism is unknown, an exacerbation of the immunological response and multisystemic involvement [20] seems to be involved. Studies investigating the pathogenesis of long COVID are essential to improve treatment and attenuate the impact.

Similar to previous studies [3, 9, 17, 21-23, 31], we found that long COVID was more prevalent in women and could be attributed to a greater propensity for women to go to a clinic [22]. Indeed, females represented 55% of the COVID group and 64% of the non-COVID group in our study. Sex hormone differences in immune response [24] and autoimmunity triggered by SARS-CoV-2 have been suggested to be involved in the disease

It is made available under a CC-BY-NC-ND 4.0 International license .

269 pathogenesis of long COVID [23]. Other studies have found that individuals with more 270 symptoms during the acute phase were at a higher risk for developing long COVID [9, 14]. 271 There are conflicting results regarding age in the risk for developing long COVID. In a 272 cohort of healthcare workers in Switzerland, the majority of whom had mild disease, young 273 age was associated with a higher risk for developing long COVID (14), in contrast to our 274 findings. Additional prospective studies including multicenter cohorts with larger sample 275 sizes and older patients should be performed to evaluate if the risk for developing long 276 COVID differs among age groups, racial groups, and ethnicities. Prospective studies to 277 develop predictive models and algorithms should be performed for the early detection of long 278 COVID cases.

279 Long COVID has different definitions. We have used the CDC's definition for long 280 COVID (September 16, 2021), that includes persistence of symptoms after four weeks of the 281 onset of disease. Recently, a WHO-coordinated Delphi consensus established a period of 282 more than three months after COVID-19 onset for the case definition of long COVID [25]. In 283 our study, only 445 of the calls were performed three months after disease onset. By this 284 definition, long COVID was detected in 68/216 (31.5%) of our patients. Residual symptoms 285 were also observed in 17/229 (7.4%) of the non-COVID-19 patients. As observed in our 286 study, the prevalence of long COVID may vary between studies in the absence of a universal 287 consensus to define long COVID [4]. This impacts the estimation of the prevalence of long 288 COVID cases worldwide.

This study has some limitations. The loss to follow-up was around 36% of patients and may have influenced the estimates of residual symptoms. Similar demographic and clinical characteristics were observed among patients that were included and the ones that were lost to follow-up. In addition, most participants were young, with mild disease, which does not permit generalizing these findings to the elderly and those with severe disease.

It is made available under a CC-BY-NC-ND 4.0 International license .

294 Moreover, the participants were aware of their diagnosis of COVID-19 when questionnaire 3

295 was applied, which may have led to an overestimation of persistent symptoms. Finally, the

short time to follow-up did not allow for an analysis of the duration of long COVID.

297 CONCLUSIONS

Long COVID was detected in 29.6% of patients with mild COVID-19 disease, with older age, female sex, and polysymptomatic acute disease as the main risk factors for persistent symptoms. Estimating the long COVID prevalence is important for preparing the healthcare system to assist and guide these patients. Further studies should be conducted to evaluate the impact of different variants of SARS-CoV-2 on long COVID and the potential

- 303 impact of vaccines in reducing residual symptoms.
- 304

305 LIST OF ABBREVIATIONS

- 306 STROBE Strengthening the Reporting of Observational Studies in Epidemiology
- 307 RT-PCR Reverse Transcriptase Polymerase Chain Reaction
- 308 REDCap Research Electronic Data Capture software
- 309 IGM/FIOCRUZ Gonçalo Moniz Institute
- 310 ICU Intensive Care Unit
- 311 SD Standard Deviation
- 312 IQR Interquartile Range
- 313

It is made available under a CC-BY-NC-ND 4.0 International license .

314 **TABLES**

315 **Table 1**: Clinical, sociodemographic characteristics and frequency of residual symptoms for

316 COVID-19 and non-COVID-19 cases.

	COVID-19 cases	Non-COVID-19 cases	
Characteristic	n = 412	n = 402	
Age	36 (28-48)	34(25-43)	
Age group			
15-29	126 (30.6%)	167 (41.5%)	
30-39	123 (29.9%)	106 (26.4%)	
40-49	75 (18.2%)	82 (20.4%)	
>50	88 (21.4%)	47 (11.7%)	
Female sex	228 (55.3%)	259 (64.4%)	
Body mass index (BMI)	27 (23.5-29.8)	26.1 (23.5-29.1)	
Number of acute symptoms	11 (8-14)	10 (7-13)	
Comorbidities	148 (35.9%)	131 (32.5%)	
Diabetes mellitus	12 (11.0%)	11 (2.7%)	
Respiratory allergy	95 (23.3%)	126 (31.3%)	
Obesity	102 (24.8%)	86 (21.4%)	
Normal	310 (75.2%)	316 (78.6%)	

It is made available under a CC-BY-NC-ND 4.0 International license .

Obese (BMI 30-34)	21 (5.1%)	17 (4.2%)
Overweight (BMI 35-39)	79 (19.2%)	67 (16.7%)
Extremely obese (BMI >40)	2 (0.5%)	2 (0.5%)
Number of comorbidities		
1	101 (24.5%)	90 (22.4%)
>1	47 (11.4%)	41 (10.2%)
Type of Hospitalization		
Outpatient (mild)	346 (84.2%)	395 (98.5%)
Hospitalization non-ICU (moderate)	59 (14.4%)	6 (1.5%)
Hospitalization ICU (severe)	6 (1.5%)	0 (0%)
At least one residual symptom > 1 month after disease onset	122 (29.6%)	24 (5.8%)
Number of residual symptoms (median)	1 (1-2)	2 (1-3)
1	65 (15.8%)	9 (2.2%)
>1	57 (13.2%)	13 (5.4%)

319

317

It is made available under a CC-BY-NC-ND 4.0 International license .

320 **Table 2**: Clinical, sociodemographic characteristics and frequency of residual symptoms for

321 COVID cases with or without sequelae.

Chamatariatia 1	No Sequelae	Sequelae	
Characteristic	n=290	n=122	
Age	35 (28, 47)	40 (32, 51)	
Age group			
15-29	99 (34.1%)	27 (22.1%)	
30-39	85 (29.3%)	38 (31.1%)	
40-49	51 (17.9%)	24 (19.7%)	
>50	55 (19.0%)	33 (27.0%)	
Female sex	151 (52.1%)	77 (63.1%)	
BMI	26.9 (23.5, 29.7)	27.2 (23.8, 30.1)	
Number of acute symptoms	11 (7, 14)	12 (9, 15)	
Comorbidities	101 (34.8%)	47 (38.5%)	
Diabetes mellitus	6 (2.1%)	6 (2.1%)	
Respiratory allergy	63 (21.9%)	32 (26.2%)	
Obesity	70 (24.1%)	32 (26.2%)	
Obese (BMI 30-34)	12 (4.1%)	9 (7.4%)	
Overweight (BMI 35-39)	57 (19.7%) 22 (18.0%)		

It is made available under a CC-BY-NC-ND 4.0 International license .

Extremely obese (BMI >40)	1 (0.3%)	1 (0.3%)
Number of comorbidities		
1	75 (25.9%)	26 (21.3%)
>1	26 (9.0%)	21 (17.2%)
Time of disease onset	3.30 (2.00, 5.10)	3.75 (2.12, 5.55)
Hospitalization	44 (15.2%)	21 (17.2%)

1. n(%) or Median (IQR)

322

323

324

It is made available under a CC-BY-NC-ND 4.0 International license .

325 Table 3. Multivariable analysis of odds ratio (lower and upper confidence intervals) for

326 presenting long COVID symptoms.

	OR	LCI*	UCI [*]	P value
Age group (reference 14-29)			
years				
30-39	1.71	0.95	3.12	0.078
40-49	2.04	1.02	4.10	0.045
≥ 50	2.44	1.29	4.66	0.006
Female sex	1.55	0.99	2.44	0.055
> 5 acute symptoms	3.15	1.37	8.55	0.012

^{*}LCI and UCI - lower and upper confidence intervals, respectively

327

328 FIGURES

It is made available under a CC-BY-NC-ND 4.0 International license .

Fig 1. Flowchart of the study population.



It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. 2: Frequency of acute and residual symptoms for COVID-19 and non-COVID-19 cases.

335

336 **DECLARATIONS**

Ethics approval and consent to participate: Informed consent was obtained from all
participants. The Ethics in Research Committee of the Gonçalo Moniz Research Center
approved this study (approval no. 4.315.319/202).

340 **Consent for publication**: Not applicable

341 Availability of data and materials: The dataset generated and/or analyzed during the 342 current study are not publicly available due to legal and ethical restrictions. Dataset are 343 available upon request.

344 **Funding**: This study was supported by MCTI/CNPq/FNDCT/MS/SCTIE/Decit (n° 07/2020)

345 MB-N, AB and VSB are research fellows from CNPq, the Brazilian National Research

346 Council. T.C-S. is a PhD student at the Post-Graduation Program in Health Sciences-UFBA,

- 347 which is supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-
- 348 Brasil, finance code 001.

349 **Competing interests**: The authors do not have conflicts of interests to declare for this work.

- 350 Authors' contributions: A.B.C.C. and V.B structured the original draft. V.B. and C.B. were
- 351 responsible for conceptualization and methodology. A.P.B., G.L.S, A.C.A.A, M.Q.A.B,
- 352 N.R.S and A.B.C.C collected data from the patients. T.C.S made the formal analysis

353	statistics. A.M.P.B. and V.B. participated in the project administration and in the funding
354	acquisition. TCS, JD, ACB, LPGC, MBN, ABN, CGB substantively revised the manuscript.
355	All authors read and approved the final manuscript.
356	Acknowledgements: We wish to thank all patients who were willing to participate in the
357	study. In addition, we would like to thank Hospital Aeroporto and Municipal Health
358	Secretariats of Irecê and Campo Formoso for logistical support and to Roberta de Carvalho
359	Freitas for patient-related support.
360 361	
362	REFERENCES
363	[1] Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global
364	Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A
365	Meta-Analysis and Systematic Review. J Infect Dis 2022.
366	https://doi.org/10.1093/infdis/jiac136.
367	[2] Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of
368	Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw
369	Open 2021;4:e2111417-e2111417.
370	https://doi.org/10.1001/JAMANETWORKOPEN.2021.11417.
371	[3] Amin-Chowdhury Z, Ladhani SN. Causation or confounding: why controls are critical for
372	characterizing long COVID. Nat Med 2021; 27:1129-30. https://doi.org/10.1038/s41591-
373	<u>021-01402-w</u> .
374	[4] Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al.
375	Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a
376	systematic review and meta-analysis. Clin Microbiol Infect 2022.
377	https://doi.org/10.1016/j.cmi.2022.01.014.

- 378 [5] Kelly BD, Gulati G, Kelly B. Long COVID: the elephant in the room n.d.
- 379 https://doi.org/10.1093/qjmed/hcab299. Accessed Apr 15, 2022.
- 380 [6] Nagib W. Home [Internet]. Genomahcov Fiocruz. Available from:
- 381 <u>http://www.genomahcov.fiocruz.br/</u>. Accessed Apr 5, 2022.
- 382 [7] CDC. COVID-19 and Your Health [Internet]. Centers for Disease Control and Prevention.
- 383 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/.
- 384 Accessed May 5, 2022.
- 385 [8] Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A,
- et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis.
- 387 Sci Reports | 123AD;11:16144. <u>https://doi.org/10.1038/s41598-021-95565-8</u>.
- 388 [9] Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al.
- 389 Attributes and predictors of long COVID. Nat Med 2021 274 2021;27:626–31.
 390 https://doi.org/10.1038/s41591-021-01292-y.
- 391 [10] EQ-5D User Guides EQ-5D [Internet]. EuroQol. 2022. Available from:
 392 https://euroqol.org/publications/user-guides/. Accessed Apr 10, 2022.
- 393 [11] Bartoszek A, Walkowiak D, Bartoszek A, Kardas G. Mental well-being (Depression,
- 394 loneliness, insomnia, daily life fatigue) during COVID-19 related home-confinement—A
- 395 study from Poland. Int J Environ Res Public Health 2020;17:1-12.
- 396 <u>https://doi.org/10.3390/ijerph17207417</u>.
- 397 [12] Usher K, Bhullar N, Jackson D. Life in the pandemic: Social isolation and mental health.
- 398 J Clin Nurs 2020;29:2756–7. <u>https://doi.org/10.1111/JOCN.15290</u>.
- 399 [13] Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. Rapid
- 400 Review The psychological impact of quarantine and how to reduce it: rapid review of the
- 401 evidence. WwwThelancetCom 2020;395. <u>https://doi.org/10.1016/S0140-6736(20)30460-8</u>.

- 402 [14] Strahm C, Seneghini M, Güsewell S, Egger T, Leal O, Brucher A, et al. Symptoms
- 403 compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection
- 404 results of a prospective multicenter cohort. Clinical Infectious Diseases. 2022 Jan 28.
- 405 <u>https://doi.org/10.1093/cid/ciac054</u>
- 406 [15] Evans RA, Leavy OC, Richardson M, Elneima O, McCauley HJC, Shikotra A, et al.
- 407 Clinical characteristics with inflammation profiling of long COVID and association with 1-
- 408 year recovery following hospitalisation in the UK: a prospective observational study. Lancet

409 Respir Med 2022;0. <u>https://doi.org/10.1016/S2213-2600(22)00127-8/</u>

- 410 [16] Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent
- 411 fatigue following SARS-CoV-2 infection is common and independent of severity of initial
- 412 infection. PLoS One 2020;15: e0240784. <u>https://doi.org/10.1371/JOURNAL.PONE.0240784</u>.
- 413 [17] Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mul G, et al. Female gender
- 414 is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect
- 415 2021; 1. <u>https://doi.org/10.1016/j.cmi.2021.11.002</u>.
- 416 [18] Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post-
- 417 COVID-19 symptoms 6 months after acute infection among hospitalized and non-
- 418 hospitalized patients. Clin Microbiol Infect 2021;27:1507–13.
- 419 <u>https://doi.org/10.1016/j.cmi.2021.05.033</u>.
- 420 [19] Kim Y, Kim S-W, Chang H-H, Kwon KT, Hwang S, Bae S. One Year Follow-Up of
- 421 COVID-19 Related Symptoms and Patient Quality of Life: A Prospective Cohort Study.
- 422 Yonsei Med J 2022;63:499–510. <u>https://doi.org/10.3349/YMJ.2022.63.6.499</u>.
- 423 [20] Abboud H, Abboud FZ, Kharbouch H, Arkha Y, El Abbadi N, El Ouahabi A. COVID-
- 424 19 and SARS-Cov-2 Infection: Pathophysiology and Clinical Effects on the Nervous System.
- 425 World Neurosurg 2020;140:49–53. <u>https://doi.org/10.1016/J.WNEU.2020.05.193</u>.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 426 [21] Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, á Steig B, Gaini S, et al.
- 427 Long COVID in the Faroe Islands: A Longitudinal Study Among Nonhospitalized Patients.
- 428 Clin Infect Dis 2021;73:e4058–63. <u>https://doi.org/10.1093/cid/ciaa1792</u>.
- 429 [22] Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-
- 430 COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective
- 431 cohort study. Lancet Reg Heal Eur 2021;6:100122.
- 432 <u>https://doi.org/10.1016/j.lanepe.2021.100122</u>.
- 433 [23] Seeßle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent
- 434 Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A
- 435 Prospective Cohort Study. Clin Infect Dis 2022;74:1191–8.
- 436 <u>https://doi.org/10.1093/cid/ciab611</u>.
- 437 [24] Stewart S, Newson L, Briggs TA, Grammatopoulos D, Young L, Gill P. Long COVID
- 438 risk a signal to address sex hormones and women's health. Lancet Reg Heal Eur 2021;11.
- 439 <u>https://doi.org/10.1016/J.LANEPE.2021.100242</u>.
- 440 [25] Soriano JB, Murthy S, Marshall JC, Relan P, Diaz J V. A clinical case definition of
- 441 post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2021.
- 442 <u>https://doi.org/10.1016/s1473-3099(21)00703-9</u>.
- 443 [26] R Core Team (2021). R: A language and environment for statistical computing. R
- 444 Foundation for Statistical Computing, Vienna, Austria. URL <u>https://www.R-project.org/</u>.
- 445 [27] Rede Genômica Fiocruz. <u>https://www.genomahcov.fiocruz.br/</u>. Accessed May 5, 2022.
- 446 [28] BioRender. <u>https://biorender.com/</u>. Accessed May 6, 2022.
- 447 [29] Ofice for National Statistics. The prevalence of long COVID symptoms and COVID-19
- 448 complications. 2020. Available from: https://www.ons.gov.uk/news/statementsandletters/
- theprevalenceofongcovidsymptomsandcovid19complications. Accessed May 20, 2022.

- 450 [30] CDC. Nearly One in Five American Adults Who Have Had COVID-19 Still Have "Long
- 451 COVID" [Internet]. Centers for Disease Control and Prevention. 2022. Available from:
- 452 https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm#:~:text=Over
- 453 all%2C%201%20in%2013%20adults,long%20COVID%20than%20younger%20adults.
- 454 Accessed May 21, 2022.
- 455 [31] Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM,
- 456 Taverner T, Chandan JS, Brown K, Simms-Williams N, Shah AD. Symptoms and risk factors
- 457 for long COVID in non-hospitalized adults. Nature Medicine. 2022 Jul 25:1-9.